NCCN Standard of Care Guidelines are updated each year with new biomarkers and associated CDx treatment options for all types of cancers. By the end of 2020 non-small cell lung cancer will have 9 molecular biomarkers to test for standard of care. Join us for this event to learn and discuss how in-house Next Generation Sequencing (NGS) and precision medicine programs can improve patient care and help your organization meet ever-evolving guidelines. CE Credits are available for this event. This event is open to all registrants.
By the conclusion of this session you will understand:
Learning Objectives:
1. Review the benefits of next generation sequencing testing for pathologists
2. Summarize the potential improvements to patient care based on bringing next
generation sequencing in-house
This virtual meeting will be conducted within OncomineWorld in our virtual auditorium. OncomineWorld is so much more than your traditional virtual event – you can navigate to many different areas and experience a new level of virtual interactivity. Within OncomineWorld you can…
Corporate Division Head Medical Oncology/Hematology, William Osler Health System
System and Core Lab Director, Diagnostic Medicine Institute, Geisinger Health
Director of Operational Optimization, Norton Healthcare